practical consequences of this methodological approach to AIDs, perhaps hypothesizing future diagnostic and therapeutic landscapes.
REVIEWER

Carlo Selmi University of Milan REVIEW RETURNED
12-Feb-2018
GENERAL COMMENTS
In this manuscript, a large consortium of authors propose to investigate using system biology 25 (in some parts there appear to be 24) diseases to identify common an unique features encompassing comics and clinical features. The study id extremely ambitious and the brief descriptions of the methods do not allow a clear evaluation of the strengths and limits of the proposal. Indeed, we are all aware that the current classification of diseases is unsatisfactory and follows more a clinical pathway rather than a mechanistic one. Major concerns arise: -the choice of the 6 control diseases has clearl overlaps, as in the case od APS and SLE -how could common clinical data help (as in the case of quality of life)? -how are ongoing treatment included in the analysis?
The study would enormously benefit from preliminary data and, possibly, by the limitation for smaller groups of diseases, as for Spa vs RA vs auto inflammatory diseases perhaps?
REVIEWER
Ujjwal Neogi Karolinska Institutet, Sweden
REVIEW RETURNED
19-Mar-2018
GENERAL COMMENTS
The study protocol by Lorenzon et al is technically sound and help to have a general picture of the mechanisms and important phenotype of autoimmune and auto-inflammatory diseases. The study will make important contributions to the field of transnational research applied to understand the important phenotype of autoimmune and autoinflammatory diseases and will generate immense data and knowledge. However some important caveat should be clarified: Can you please clarify the 2 acronyms: P14 HD? And MAIs? -Please spell out these at the end of the manuscript also.
While not designed at this time to include pediatric patients, if this study is successful, the authors should consider a similar study with children to see if results are similar or distinct.
We thank the reviewer for her comments on our manuscript which indeed describes a protocol study. The results from omics and clinical data analysis will be published in dedicated articles.
Regarding acronyms: -HD stands for healthy donors but since w also use healthy volunteers in the manuscript to design the same group of patient, we harmonized the vocabulary and choose to use Healthy volunteers (HV). The abbreviation has been added to the "list of abbreviations" section. -MAIs is a typos, it should have been written AIDs.
We agree with the reviewer that it would be of utmost importance to perform a similar study on pediatric patients for relevant diseases, although the design will have to be slightly downscaled to some omics due to obvious blood harvesting limitations. Hopefully Transimmunom will be extended to this perspective in the future.
Reviewer: 2 Reviewer Name: Lia Ginaldi Institution and Country: L'Aquila University, Italy
Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below The paper is interesting and well structured. The authors emphasize the translationality, multidisciplinarity and possible clinical effects of the proposed methodological approach. They describe the TRANSIMMUNOM trial and propose it as a tool to revisit the nosology of autoimmune and autoinflammatory diseases through classical and system biology approachs. Only step 1 of the study has been completed, step 2 is ongoing and the results are still to be collected and processed and their clinical relapse is therefore to be verified, However, the paper is interesting and innovative as it re-proposes a new reading register of the wide spectrum of autoinflammatory and autoimmune diseases, in agreement with other authors that I would recommend to insert in the bibliography (Doria A et al. Chem. 2013; 21:261-269) . I would also suggest stressing more in the discussion the possible practical consequences of this methodological approach to AIDs, perhaps hypothesizing future diagnostic and therapeutic landscapes.
We thank the reviewer for her nice comments on our manuscript and on the project. We included the very good reviews she suggested in the introduction and discussion sections (References 3 and 4 of the new list). We totally agree that this approach should ultimately lead to biomarker discovery and new therapeutic approaches. We are very grateful of this comment and added a paragraph in the discussion section: "TRANSIMMUNOM has the potential to provide fundamental data knowledge about the pathophysiology of AIDs and to redefine their nosology. Indeed, we and others already showed the power of systems immunology to better understand biological processes associated with autoimmune and autoinflammatory disease [27, 28, 30, [44] [45] [46] [47] [48] [49] Systems immunology is now seen as the future for new biomarkers and therapeutic target discovery, validated in onco-immunology [50] [51] [52] . With the advance of high-throughput data modelling and integrative analyses, it has been already shown that blood can be used to follow and even predict biological process undergoing in distant tissue [46, [53] [54] [55] [56] . We have no doubt that with the unprecedented endeavor and deep clinical and immune profiling to be achieved in Transimmunom, we will contribute to identify new disease biomarkers and possibly new therapeutic targets. "
Reviewer: 3 Reviewer Name: Carlo Selmi Institution and Country: University of Milan
Please state any competing interests or state 'None declared': none declared Please leave your comments for the authors below In this manuscript, a large consortium of authors propose to investigate using system biology 25 (in some parts there appear to be 24) diseases to identify common an unique features encompassing comics and clinical features.
We thank the reviewer for his comments. The number of diseases is 25 (19 AIDs and 6 control diseases). We corrected the manuscript accordingly.
The study id extremely ambitious and the brief descriptions of the methods do not allow a clear evaluation of the strengths and limits of the proposal. Indeed, we are all aware that the current classification of diseases is unsatisfactory and follows more a clinical pathway rather than a mechanistic one. Major concerns arise: -the choice of the 6 control diseases has clear overlaps, as in the case od APS and SLE We thank the reviewer for his comment. We modified the "Study design and set-up section" by adding the following text: "Control diseases were selected as to contrast with the pathophysiology of the autoimmune and inflammatory diseases under study. They were chosen as having overlapping clinical manifestations but different physiopathological mechanisms: (i) diseases with mainly an inflammatory versus an autoimmune driver (type 2 diabetes versus type 1 diabetes; osteoarthritis versus RA), (ii) different genetic mutations (TRAPS-CAPS versus FMF, (iii) genetic disease versus autoimmune disease of a given tissue (muscular dystrophy versus myositis) and (iv) autoimmune disease that may arise as primary or secondary to other pathologies (primary APLS versus SLE)"
-how could common clinical data help (as in the case of quality of life)?
It is known that quality of life (such as smocking habit, alcohol, type of food, …) may impact on disease outcome and severity. Clinical data have been coded on an eCRF following CDASH harmonization. We are able to export any clinical information in a coded manner and use it for correlation analysis with other clinical data as well as with omics.
-how are ongoing treatment included in the analysis?
Treatments, particularly immunomodulating drugs, were coded in an harmonized manner regarding possible formulas, doses and dosage regimens. They will be included in the analysis as any other clinical data.
Data analysis is ongoing and results will be part of dedicated articles. However, we agree with the reviewer that we first have to focus on smaller group of well characterized diseases. Actually, this is our ongoing work, with a major focus on T1D, T2D, RA and SpA.
Reviewer: 4 Reviewer Name: Ujjwal Neogi Institution and Country: Karolinska Institutet, Sweden
Please state any competing interests or state 'None declared': None declared Please leave your comments for the authors below The study protocol by Lorenzon et al is technically sound and help to have a general picture of the mechanisms and important phenotype of autoimmune and auto-inflammatory diseases. The study will make important contributions to the field of transnational research applied to understand the important phenotype of autoimmune and autoinflammatory diseases and will generate immense data and knowledge. However some important caveat should be clarified:
Major Comments: 1. Author mention the study "observational case-controlled clinical trial". Is this a trial or a casecontrolled cohort study. If author want to call it as trial, authors should present the primary outcome, secondary outcome etc in a more conventional manner. Transimmunom is a case-controlled trial registered on clinicaltrails.gov, where primary and secondary outcome are well described. Because of text length limitation, we do not detail them in the "Study aim" section. Instead we indicated where to find them by adding the following sentence: "More details on primary and secondary outcome measures can be found on https://clinicaltrials.gov/ct2/show/NCT02466217."
2. Author stated that the study approach is system biology approach. However the classical definition of the Systems biology is "the computational and mathematical modeling of complex biological systems." Authors have not presented any analysis plan for the same. To this reviewer it's a "integrated multi-omics study". Please provide the system biology analysis plan, different methods for integration etc.
In Transimmunom we aim at analysing and modelling the complex and multiscale set of data that are generated using classical statistical approaches, as well as integrative approaches. We believe that altogether these approaches fall into the definition of systems biology, a holistic approach allowing to identify relationships between multiscale and multiparametric data. The computational and mathematical modelling aspects being the means used to identify these relationships. Therefore, we clarified the section "Data analysis strategy" as follows (added text in bold):
"Classical statistical analyses and modeling as well as integrative analyses will be used to identify potential biomarkers of disease as well as new therapeutic targets. As a general design, the analysis approach consist in i) performing quality control on all the data collected using dedicated tools and solutions publically available (including clinical data through a thorough eCRF monitoring and validation), ii) implementing supervised and classical statistical methods mastered in the team [23, 24] , we will analyse parameters modulation (such as protein or gene expression level for cytokines and transcriptome, mean fluorescence intensity (MFI) or percentage for immunophenotyping, diversity for microbiome and TCR repertoire), iii) in parallel, we will implement unsupervised modelling methods publically available or developed in the laboratory [25] [26] [27] [28] [29] [30] [31] [32] [33] in order to identify more complex or hidden parameter modulations within each type of data sets, such as signature discovery [29] [30] [31] [32] 34] , and finally 4) once we will have complete multiparametric datasets for each subject, we will perform integrated analysis using methods relying on Regularized Generalized Canonical Correlation Analysis (RGCCA) and variations [34] [35] [36] [37] [38] , dedicated to the analysis of structured data sets with the aim of deciphering their relationships.. Noteworthy, biomarkers can be discovered without full knowledge of their biological meaning. This is well exemplified in cancer where resistance or sensitivity to chemotherapy can be predicted using biomarkers without understanding the underlying mechanisms. We will thus complete our pragmatic search for biomarkers by more supervised cognitive studies by collating results from our investigations with results in the literature."
